• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lipoprotein(a) association with residual risk: what has inflammation got to do with it?

作者信息

Farukhi Zareen M, Mora Samia

机构信息

Center for Lipid Metabolomics, Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02215, USA.

Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

出版信息

Eur Heart J. 2024 Mar 27;45(12):1055-1057. doi: 10.1093/eurheartj/ehae045.

DOI:10.1093/eurheartj/ehae045
PMID:38320259
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10972682/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627c/10972682/ccaa64df5491/ehae045_ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627c/10972682/ccaa64df5491/ehae045_ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627c/10972682/ccaa64df5491/ehae045_ga1.jpg

相似文献

1
Lipoprotein(a) association with residual risk: what has inflammation got to do with it?脂蛋白(a)与残余风险的关联：炎症与之有何关系？
Eur Heart J. 2024 Mar 27;45(12):1055-1057. doi: 10.1093/eurheartj/ehae045.
2
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.低密度脂蛋白水平较低时的残余心血管风险：残留颗粒、脂蛋白(a)与炎症
Clin Chem. 2021 Jan 8;67(1):143-153. doi: 10.1093/clinchem/hvaa252.
3
Residual cardiovascular risk: When should we treat it?残余心血管风险：我们何时应进行治疗？
Eur J Intern Med. 2024 Feb;120:17-24. doi: 10.1016/j.ejim.2023.10.013. Epub 2023 Oct 14.
4
Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome.最常见的残余风险因素（残余胆固醇、脂蛋白(a)和炎症）对他汀类药物治疗的慢性冠状动脉综合征患者预后的协同作用。
J Transl Med. 2022 May 26;20(1):243. doi: 10.1186/s12967-022-03448-x.
5
Coronary heart disease risk: Low-density lipoprotein and beyond.冠心病风险：低密度脂蛋白及其他。
Trends Cardiovasc Med. 2022 May;32(4):181-194. doi: 10.1016/j.tcm.2021.04.002. Epub 2021 Apr 17.
6
Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population.尽管脂蛋白(a)升高与主动脉瓣狭窄和心肌梗死有因果关系，但它不会导致低度炎症：一项来自普通人群的 100578 人的研究。
J Clin Endocrinol Metab. 2015 Jul;100(7):2690-9. doi: 10.1210/jc.2015-1096. Epub 2015 May 4.
7
Lipoprotein(a) and cardiovascular disease: Make use of the knowledge we have.脂蛋白(a)与心血管疾病：运用我们所掌握的知识。
Atherosclerosis. 2022 Dec;363:75-77. doi: 10.1016/j.atherosclerosis.2022.11.016. Epub 2022 Nov 23.
8
Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk.脂蛋白(a)：空腹和非空腹水平、炎症与心血管风险。
Atherosclerosis. 2014 May;234(1):95-101. doi: 10.1016/j.atherosclerosis.2014.01.049. Epub 2014 Feb 12.
9
Highlighting Residual Atherosclerotic Cardiovascular Disease Risk.突出残留的动脉粥样硬化性心血管疾病风险。
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):e1-e9. doi: 10.1161/ATVBAHA.118.311999.
10
Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels.脂蛋白(a)对卒中复发的影响在 LDL-C（低密度脂蛋白）和炎症水平较低时减弱。
Stroke. 2022 Aug;53(8):2504-2511. doi: 10.1161/STROKEAHA.121.034924. Epub 2022 Apr 12.

本文引用的文献

1
C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project.C-反应蛋白修饰脂蛋白（a）相关的冠心病风险：BiomarCaRE 项目。
Eur Heart J. 2024 Mar 27;45(12):1043-1054. doi: 10.1093/eurheartj/ehad867.
2
Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein.脂蛋白(a)与动脉粥样硬化血栓形成和主动脉瓣狭窄相关，且独立于C反应蛋白。
Eur Heart J. 2023 Apr 21;44(16):1449-1460. doi: 10.1093/eurheartj/ehad055.
3
Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention.
脂蛋白（a）、高敏C反应蛋白与接受经皮冠状动脉介入治疗患者的心血管风险
Atherosclerosis. 2022 Dec;363:109-116. doi: 10.1016/j.atherosclerosis.2022.10.013. Epub 2022 Oct 25.
4
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.脂蛋白(a)与动脉粥样硬化性心血管疾病及主动脉瓣狭窄：欧洲动脉粥样硬化学会共识声明。
Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361.
5
Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.脂蛋白(a)-动脉粥样硬化、动脉血栓形成和炎症的十字路口。
Biomolecules. 2021 Dec 24;12(1):26. doi: 10.3390/biom12010026.
6
High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): Multi-Ethnic Study of Atherosclerosis.载脂蛋白(a)的心血管风险受高敏 C 反应蛋白修饰：动脉粥样硬化多民族研究。
J Am Coll Cardiol. 2021 Sep 14;78(11):1083-1094. doi: 10.1016/j.jacc.2021.07.016.
7
Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation.除了脂蛋白(a)的血浆测量值之外：脂蛋白(a)与炎症。
Pharmacol Res. 2021 Jul;169:105689. doi: 10.1016/j.phrs.2021.105689. Epub 2021 May 23.
8
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.在高动脉粥样硬化风险患者中使用 ziltivekimab 抑制白介素-6（RESCUE）：一项双盲、随机、安慰剂对照、2 期试验。
Lancet. 2021 May 29;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1. Epub 2021 May 17.
9
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.C 反应蛋白对高血管风险疾病经优化治疗患者脂蛋白(a)相关心血管风险的影响：ACCELERATE 试验的一项预设次要分析。
JAMA Cardiol. 2020 Oct 1;5(10):1136-1143. doi: 10.1001/jamacardio.2020.2413.
10
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.脂蛋白(a)降低与心血管疾病患者。
N Engl J Med. 2020 Jan 16;382(3):244-255. doi: 10.1056/NEJMoa1905239. Epub 2020 Jan 1.